Medicale Corp. reported a net loss of $41,153 for the fiscal year ending September 30, 2025, a decrease of 29% from the net loss of $58,213 recorded in the previous fiscal year. The company's operating expenses also declined by 39% to $33,493, down from $54,707 in 2024, primarily due to reduced consulting fees. Despite these reductions in losses and expenses, Medicale Corp. has not yet generated any revenue since its incorporation in 2020, and it continues to operate at a loss as it develops its business model.
The company's financial position has deteriorated, with current liabilities increasing to $33,652 as of September 30, 2025, compared to $15,507 the previous year. This rise in liabilities is attributed to increased accounts payable and accrued liabilities. Medicale Corp. reported a working capital deficiency of $33,652, worsening from a deficit of $15,348 in 2024. The company’s accumulated deficit has now reached $216,998, raising concerns about its ability to continue as a going concern without additional capital.
Medicale Corp. has not commenced any operational activities and has no employees, with its officers and directors contributing their time at no cost. The company is focused on preserving cash and raising capital to fund its future operations. As of January 9, 2026, Medicale Corp. had 11 shareholders of record and 5,920,000 shares of common stock outstanding. The company’s shares are traded on the Pink Sheets under the symbol "MCLE," but the market for these shares is characterized by low trading volumes and price volatility.
In terms of strategic developments, Medicale Corp. underwent a significant change in ownership in December 2022 when Magenta Acres, Inc. acquired a majority stake in the company. This acquisition has allowed Magenta Acres to control the direction of Medicale Corp. Additionally, the company has implemented cybersecurity risk management procedures to protect its information technology systems, although it has not reported any material cybersecurity incidents to date.
Looking ahead, Medicale Corp. acknowledges that it will need to secure additional investment capital to fund its operations and achieve financial viability. The management has expressed intentions to position the company for future fundraising efforts, although there are no guarantees of success. The company’s financial statements indicate that it may need to modify, delay, or abandon its business plans if it fails to generate positive cash flow or obtain necessary financing.
About Medicale Corp.
Medicale Corp. is a development-stage company focused on offering consulting services and distributing dietary supplements. It operates in the health and wellness sector, targeting consumers seeking nutritional products. The company emphasizes product distribution, strategic capital raising, and maintaining compliance. With limited assets and no revenue, it relies on investor funding and debt instruments, aiming to establish a market presence in the dietary supplement industry.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.